XML 188 R70.htm IDEA: XBRL DOCUMENT v3.24.3
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Dec. 29, 2023
Jun. 28, 2023
Feb. 28, 2023
May 17, 2022
Dec. 20, 2018
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Oct. 24, 2023
Interest income           $ 101,236 $ 110,596 $ 309,031 $ 555,281 $ 662,859 $ 236,349  
Principal repayments               $ 26,408 118,847 27,786 99,906  
Outstanding principal balance                   1,570,886 $ 2,158,417  
General and administrative expenses                   $ 164,859    
Common stock share issued           23,346,023   23,346,023   15,982,472 10,605,412  
Accrued interest           $ 185,561   $ 185,561   $ 166,348 $ 275,547  
Accounts receivable balance           17,484,240   17,484,240   19,759,254 23,691,997  
Prepaid expenses and other current assets - related party           1,914,881   1,914,881   1,811,911 1,546,225  
Revenue           12,411,048 12,823,797 40,202,238 37,537,003 53,376,874 50,347,652  
George Terzis [Member]                        
Unpaid salaries and bonuses           731,000   731,000   98,000    
Unpaid salaries and bonuses dues           188,000   188,000        
Common stock share issued                       51,485
Basotho Investment Limited [Member]                        
General and administrative expenses               92,700   $ 10,300    
Common stock share issued                   120,000    
Grigorios Siokas [Member]                        
Outstanding principal balance           21,158   21,158   $ 13,257 12,821  
Foreign curreny translation               1,525   436 64,729  
Borrowing         $ 1,718,400              
Interest rate         4.70%              
Maturity date         Mar. 18, 2019              
Accrued interest                   0 206,355  
Cana Holdings Laboratories Holding Limited [Member]                        
Interest income     $ 148,789                  
Secured promissory note     $ 4,457,520                  
Description related to interest on principal     Interest on the Principal Amount under this Note shall accrue at a rate equal to Five Percent (5%) plus one month LIBOR per annum (5.47% as of December 31, 2023)                  
DOC Pharma S.A. [Member]                        
Interest income               143,000   217,476    
Principal repayments               334,350 135,467 442,480    
Interest repayments               $ 155,440   $ 232,210    
Interest rate               5.50%   5.50%    
Loan term               10 years   10 years    
Maturity date               Dec. 31, 2032   Dec. 01, 2032    
Accounts payable and accrued expenses - related party           72,968   $ 72,968   $ 34,217 201,991  
Prepaid expenses                     7,599,545  
Accounts receivable - related party           2,448,517   2,448,517   2,386,721 2,070,570  
Prepaid expenses and other current assets - related party           6,393,642   $ 6,393,642   4,347,184 3,320,345  
Prepaid balance                   $ 4,279,200    
Agreement terminate               Dec. 31, 2025   Dec. 31, 2025    
Pieces per product               1,000 pieces   1,000 pieces    
Purchased of additional licenses               $ 525,461   $ 525,461    
Loan current portion           445,800   445,800   442,480 427,720  
Loan non-current portion           3,232,050   3,232,050   3,539,840 3,851,280  
Inventroy purchase           85,073 456,257 510,711 1,057,621 1,365,324 1,755,103  
Revenue           40,370 61,163 581,862 43,107 619,637 1,058,780  
Monthly basis instalments           37,150   37,150   35,660    
Purchase of branded pharmaceuticals $ 3,539,840 $ 1,965,600                    
Description of research and development       The total cost of this project will be €1,425,000 plus VAT and will be done over three phases as follows: Design & Development (€725,000); Control and Product Manufacturing (€250,000) and Clinical Study and Research (€450,000). SkyPharm has bought a total of as of 81 licenses at value of €554,500 ($593,204) which is 38.91% of the total cost, as of December 31, 2022                
DOC Pharma S.A. [Member] | Inventories Related Agreement [Member]                        
Inventroy purchase           38,096 455,586 175,123 1,048,557 1,237,467 1,742,282  
Dimitrios Goulielmos [Member]                        
Outstanding principal balance           11,368   11,368   11,283 10,912  
Foreign curreny translation               85   371 19,568  
Panagiotis Kozaris [Member]                        
Shares owned           0 51,159     51,159 143,056  
Prepaid expenses           194,215   194,215   194,215 143,056  
Maria Kozari [Member]                        
Accounts receivable balance           1,123,835   1,123,835   1,142,402 760,025  
Net sales           113,161 $ 310,126 122,969 $ 359,760 480,029 $ 463,467  
Kanarogloy & Sia Epe [Member]                        
Accounts payable and accrued expenses - related party           $ 29,832   $ 29,832   $ 85,332